The company is highlighted as an unstoppable stock to buy and hold for the next three years and one of the best strong buy healthcare stocks. It recently reported its Q4 and full-year 2025 results, entering 2026 with momentum. While Mizuho cut its price target from $211 to $204 on February 24, it maintained an Outperform rating on the shares following the earnings report.